Drug Information
Drug (ID: DG00208) and It's Reported Resistant Information
Name |
Everolimus
|
||||
---|---|---|---|---|---|
Synonyms |
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(5 diseases)
Breast cancer [ICD-11: 2C60]
[2]
Kidney cancer [ICD-11: 2C90]
[3]
Pancreatic cancer [ICD-11: 2C10]
[4]
Prostate hyperplasia [ICD-11: GA90]
[5]
Thyroid cancer [ICD-11: 2D10]
[6]
|
||||
Target | Serine/threonine-protein kinase mTOR (mTOR) | MTOR_HUMAN | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C53H83NO14
|
||||
IsoSMILES |
C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC
|
||||
InChI |
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
|
||||
InChIKey |
HKVAMNSJSFKALM-GKUWKFKPSA-N
|
||||
PubChem CID | |||||
ChEBI ID | |||||
TTD Drug ID | |||||
VARIDT ID | |||||
INTEDE ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
EADR: Epigenetic Alteration of DNA, RNA or Protein
RTDM: Regulation by the Disease Microenvironment
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Pancreatic cancer [ICD-11: 2C10]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) | [4] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Pancreatic neuroendocrine tumor [ICD-11: 2C10.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | PI3K/AKT/mTOR signaling pathway | Activation | hsa04151 | |
CXCR4-CXCL12-CXCR7 signaling pathway | Activation | hsa04061 | ||
In Vitro Model | A498 cells | Kidney | Homo sapiens (Human) | CVCL_1056 |
SN12C cells | Kidney | Homo sapiens (Human) | CVCL_1705 | |
Experiment for Molecule Alteration |
Western blotting assay | |||
Mechanism Description | When the CXCR4-CXCL12-CXCR7 pathway is activated through CXCL12 in human renal cancer cells were, SN12C and A498, CXCL12 induced the mTOR targets p-P70S6K and p-4EBP1.The combination therapy of mTOR inhibitors with the CXCR4-CXCL12-CXCR7 axis inhibitors in renal cancer tumors could overcome the Everolimus resistance. | |||
Key Molecule: Ribosomal protein S6 kinase beta-1 (RPS6KB1) | [4] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Pancreatic neuroendocrine tumor [ICD-11: 2C10.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | PI3K/AKT/mTOR signaling pathway | Activation | hsa04151 | |
CXCR4-CXCL12-CXCR7 signaling pathway | Activation | hsa04061 | ||
In Vitro Model | A498 cells | Kidney | Homo sapiens (Human) | CVCL_1056 |
SN12C cells | Kidney | Homo sapiens (Human) | CVCL_1705 | |
Experiment for Molecule Alteration |
Western blotting assay | |||
Mechanism Description | When the CXCR4-CXCL12-CXCR7 pathway is activated through CXCL12 in human renal cancer cells were, SN12C and A498, CXCL12 induced the mTOR targets p-P70S6K and p-4EBP1.The combination therapy of mTOR inhibitors with the CXCR4-CXCL12-CXCR7 axis inhibitors in renal cancer tumors could overcome the Everolimus resistance. |
Breast cancer [ICD-11: 2C60]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Mth938 domain-containing protein (AAMDC) | [2] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Breast cancer [ICD-11: 2C60.3] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Activation | hsa04151 | ||
In Vitro Model | MCF-7 cells | Breast | Homo sapiens (Human) | CVCL_0031 |
SkBR3 cells | Breast | Homo sapiens (Human) | CVCL_0033 | |
MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 | |
HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 | |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
BT549 cells | Breast | Homo sapiens (Human) | CVCL_1092 | |
MCF-12A cells | Breast | Homo sapiens (Human) | CVCL_3744 | |
SUM159 cells | Breast | Homo sapiens (Human) | CVCL_5423 | |
SUM44PE cells | Breast | Homo sapiens (Human) | CVCL_3424 | |
SUM52PE cells | Breast | Homo sapiens (Human) | CVCL_3425 | |
In Vivo Model | BALB/cJ Foxn1/Arc nude mice xenografts model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
CellTiter-Glo 2.0 luminescence assay protocol assay | |||
Mechanism Description | High AAMDC expression is associated with sensitization to dactolisib and everolimus, and these PI3k-mTOR inhibitors exhibit synergistic interactions with anti-estrogens in IntClust2 models. Ectopic AAMDC expression is sufficient to activate AkT signaling, resulting in estrogen-independent tumor growth. Thus, AAMDC-overexpressing tumors may be sensitive to PI3k-mTORC1 blockers in combination with anti-estrogens. |
Prostate cancer [ICD-11: 2C82]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Growth arrest specific 5 (GAS5) | [1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Disease | Prostate cancer [ICD-11: 2C82.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | DU-145 cells | Prostate | Homo sapiens (Human) | CVCL_0105 |
LNCaP cells | Prostate | Homo sapiens (Human) | CVCL_0395 | |
PC3 cells | Prostate | Homo sapiens (Human) | CVCL_0035 | |
22RV1 cells | Prostate | Homo sapiens (Human) | CVCL_1045 | |
PNT2C2 cells | Prostate | Homo sapiens (Human) | CVCL_4889 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
GAS5 assay; MTS assay | |||
Mechanism Description | First generation mTORC1, combined mTORC1/mTORC2 and dual PI3k/mTOR inhibitors all increased cellular GAS5 levels and inhibited culture growth in androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU 145) cell lines. The latter exhibited low endogenous GAS5 expression, and GAS5 silencing in LNCaP and 22Rv1 cells decreased the sensitivity to mTOR inhibitors, whereas transfection of GAS5 LncRNA sensitized PC-3 and DU 145 cells to these agents. |
Kidney cancer [ICD-11: 2C90]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Regulation by the Disease Microenvironment (RTDM) | ||||
Key Molecule: hsa-mir-92a | [3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Kidney cancer [ICD-11: 2C90.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Caki-1 cells | Kidney | Homo sapiens (Human) | CVCL_0234 |
786-O cells | Kidney | Homo sapiens (Human) | CVCL_1051 | |
ACHN cells | Pleural effusion | Homo sapiens (Human) | CVCL_1067 | |
A498 cells | Kidney | Homo sapiens (Human) | CVCL_1056 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | NC886 also promotes renal cancer cell drug-resistance to Sunitinib or Everolimus by promoting EMT through Rock2 phosphorylation-mediated nuclear translocation of beta-catenin. |
Thyroid cancer [ICD-11: 2D10]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase mTOR (mTOR) | [6] | |||
Molecule Alteration | Missense mutation | p.F2108L |
||
Resistant Disease | Thyroid carcinoma [ICD-11: 2D10.4] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | mTOR signaling pathway | Activation | hsa04150 | |
Experiment for Molecule Alteration |
Whole-exome sequencing assay; Whole-genome sequencing assay | |||
Experiment for Drug Resistance |
Computerized tomography assay | |||
Mechanism Description | On the basis of these findings, we hypothesized that mTORF2108L causes resistance to allosteric mTOR inhibition by preventing the binding of the drug to the protein. |
ICD-16: Genitourinary system diseases
Prostate hyperplasia [ICD-11: GA90]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: NPR2 like, GATOR1 complex subunit (NPRL2) | [5] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Prostate hyperplasia [ICD-11: GA90.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | mTOR signaling pathway | Inhibition | hsa04150 | |
In Vitro Model | PC3 cells | Prostate | Homo sapiens (Human) | CVCL_0035 |
RWPE-1 cells | Prostate | Homo sapiens (Human) | CVCL_3791 | |
PCa LNCaP cells | Prostate | Homo sapiens (Human) | CVCL_D575 | |
In Vivo Model | Balb/c athymic nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blotting assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.NPRL2-silencing increased the activity of mTOR signaling, and the autophagy attenuation induced by NPRL2-silencing in EVS-treated CRPC cells was associated with the increase of apoptosis. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.